Literature DB >> 16390950

Armored RNA as virus surrogate in a real-time reverse transcriptase PCR assay proficiency panel.

S K Hietala1, B M Crossley.   

Abstract

In recent years testing responsibilities for high-consequence pathogens have been expanded from national reference laboratories into networks of local and regional laboratories in order to support enhanced disease surveillance and to test for surge capacity. This movement of testing of select agents and high-consequence pathogens beyond reference laboratories introduces a critical need for standardized, noninfectious surrogates of disease agents for use as training and proficiency test samples. In this study, reverse transcription-PCR assay RNA targets were developed and packaged as armored RNA for use as a noninfectious, quantifiable synthetic substitute for four high-consequence animal pathogens: classical swine fever virus; foot-and-mouth disease virus; vesicular stomatitis virus, New Jersey serogroup; and vesicular stomatitis virus, Indiana serogroup. Armored RNA spiked into oral swab fluid specimens mimicked virus-positive clinical material through all stages of the reverse transcription-PCR testing process, including RNA recovery by four different commercial extraction procedures, reverse transcription, PCR amplification, and real-time detection at target concentrations consistent with the dynamic ranges of the existing real-time PCR assays. The armored RNA concentrations spiked into the oral swab fluid specimens were stable under storage conditions selected to approximate the extremes of time and temperature expected for shipping and handling of proficiency panel samples, including 24 h at 37 degrees C and 2 weeks at temperatures ranging from ambient room temperature to -70 degrees C. The analytic test performance, including the reproducibility over the dynamic range of the assays, indicates that armored RNA can provide a noninfectious, quantifiable, and stable virus surrogate for specific assay training and proficiency test purposes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16390950      PMCID: PMC1351936          DOI: 10.1128/JCM.44.1.67-70.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Multicenter proficiency testing of nucleic acid amplification methods for the detection of enteroviruses.

Authors:  K E Van Vliet; P Muir; J M Echevarria; P E Klapper; G M Cleator; A M Van Loon
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

2.  Generic scheme for independent performance assessment in the molecular biology laboratory.

Authors:  Lyndsey Birch; Claire A English; Malcolm Burns; Jacquie T Keer
Journal:  Clin Chem       Date:  2004-07-01       Impact factor: 8.327

Review 3.  Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction.

Authors:  Stephen A Bustin; Tania Nolan
Journal:  J Biomol Tech       Date:  2004-09

4.  High-throughput real-time RT-PCR assay to detect the exotic Newcastle Disease Virus during the California 2002--2003 outbreak.

Authors:  Beate M Crossley; Sharon K Hietala; Liu-Mei Shih; Lou Lee; Evan W Skowronski; Alex A Ardans
Journal:  J Vet Diagn Invest       Date:  2005-03       Impact factor: 1.279

5.  Ribonuclease-resistant RNA controls (Armored RNA) for reverse transcription-PCR, branched DNA, and genotyping assays for hepatitis C virus.

Authors:  C R WalkerPeach; M Winkler; D B DuBois; B L Pasloske
Journal:  Clin Chem       Date:  1999-12       Impact factor: 8.327

6.  TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening.

Authors:  C Drosten; E Seifried; W K Roth
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Reliability of nucleic acid amplification methods for detection of Chlamydia trachomatis in urine: results of the first international collaborative quality control study among 96 laboratories.

Authors:  Roel P Verkooyen; Gerda T Noordhoek; Paul E Klapper; Jim Reid; Jurjen Schirm; Graham M Cleator; Margareta Ieven; Gunnar Hoddevik
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Preclinical evaluation of two real-time, reverse transcription-PCR assays for detection of the severe acute respiratory syndrome coronavirus.

Authors:  Adam M Bressler; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

9.  Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus.

Authors:  Johnny D Callahan; Fred Brown; Fernando A Osorio; Jung H Sur; Ed Kramer; Gary W Long; Juan Lubroth; Stefanie J Ellis; Katina S Shoulars; Kristin L Gaffney; Daniel L Rock; William M Nelson
Journal:  J Am Vet Med Assoc       Date:  2002-06-01       Impact factor: 1.936

10.  Rapid detection of classical swine fever virus by a portable real-time reverse transcriptase PCR assay.

Authors:  G R Risatti; J D Callahan; W M Nelson; M V Borca
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more
  24 in total

1.  Application of Faecalibacterium 16S rDNA genetic marker for accurate identification of duck faeces.

Authors:  Da Sun; Chuanren Duan; Yaning Shang; Yunxia Ma; Lili Tan; Jun Zhai; Xu Gao; Jingsong Guo; Guixue Wang
Journal:  Environ Sci Pollut Res Int       Date:  2016-01-08       Impact factor: 4.223

2.  Implementation of a T4 extraction control for molecular assays of cerebrospinal fluid and stool specimens.

Authors:  Jill E Gerriets; Timothy C Greiner; Catherine L Gebhart
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

3.  External quality assessment for Avian Influenza A (H7N9) Virus detection using armored RNA.

Authors:  Yu Sun; Tingting Jia; Yanli Sun; Yanxi Han; Lunan Wang; Rui Zhang; Kuo Zhang; Guigao Lin; Jiehong Xie; Jinming Li
Journal:  J Clin Microbiol       Date:  2013-10-02       Impact factor: 5.948

Review 4.  Design of virus-based nanomaterials for medicine, biotechnology, and energy.

Authors:  Amy M Wen; Nicole F Steinmetz
Journal:  Chem Soc Rev       Date:  2016-07-25       Impact factor: 54.564

5.  External quality assessment for enterovirus 71 and coxsackievirus A16 detection by reverse transcription-PCR using armored RNA as a virus surrogate.

Authors:  Liqiong Song; Shipeng Sun; Bo Li; Yang Pan; Wenli Li; Kuo Zhang; Jinming Li
Journal:  J Clin Microbiol       Date:  2011-08-24       Impact factor: 5.948

6.  Inhibition monitoring in veterinary molecular testing.

Authors:  Lifang Yan; Kathy L Toohey-Kurth; Beate M Crossley; Jianfa Bai; Amy L Glaser; Rebecca L Tallmadge; Laura B Goodman
Journal:  J Vet Diagn Invest       Date:  2019-11-18       Impact factor: 1.279

Review 7.  Molecular detection and genotyping of noroviruses.

Authors:  Ambroos Stals; Elisabeth Mathijs; Leen Baert; Nadine Botteldoorn; Sarah Denayer; Axel Mauroy; Alexandra Scipioni; Georges Daube; Katelijne Dierick; Lieve Herman; Els Van Coillie; Etienne Thiry; Mieke Uyttendaele
Journal:  Food Environ Virol       Date:  2012-11-04       Impact factor: 2.778

8.  Quantitative assessment of the sensitivity of various commercial reverse transcriptases based on armored HIV RNA.

Authors:  John B A Okello; Linda Rodriguez; Debi Poinar; Kirsten Bos; Andrew L Okwi; Gabriel S Bimenya; Nelson K Sewankambo; Kenneth R Henry; Melanie Kuch; Hendrik N Poinar
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

9.  Armored long RNA controls or standards for branched DNA assay for detection of human immunodeficiency virus type 1.

Authors:  Sien Zhan; Jinming Li; Ruihuan Xu; Lunan Wang; Kuo Zhang; Rui Zhang
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

10.  Preparation of armored RNA as a control for multiplex real-time reverse transcription-PCR detection of influenza virus and severe acute respiratory syndrome coronavirus.

Authors:  Xin-Fen Yu; Jing-Cao Pan; Rong Ye; Hai-Qing Xiang; Yu Kou; Zhi-Cheng Huang
Journal:  J Clin Microbiol       Date:  2007-12-26       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.